muscle atrophy muscle wasting Sarcopenia
Conditions
Interventions
n.a.
Sponsors
Universiteit Maastricht
Eligibility
Age
18 Years to 99 Years
Inclusion criteria
Inclusion criteria: Hip fracture or osteoarthritis of the hip, >65 years of age, operative treatment Healthy elderly subjects, mentally competent, age-matched with fracture patients
Exclusion criteria
Exclusion criteria: - Co-morbidities and neuromuscular disorders of the lower limbs severely interacting with mobility - Co-morbidities severely interacting with muscle metabolism of the lower limbs - Known renal malfunction (Known renal malfunction without documented approval from nephrologist) - Known allergy to milk, milk products and soy - Known galactosaemia - A life-expectancy of less than 6 months
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary parameters in this study are the cross-sectional area of the quadriceps muscle and the cross-sectional area of type I and type II skeletal muscle fibers. | — |
Secondary
| Measure | Time frame |
|---|---|
| Secondary outcome parameters in this study are satellite cell content in the type I en type II skeletal muscle fibers, functional outcome 6 months after hospital admission (determined by the use of the PASE score and Hip Fracture Functional Recovery Scale), and quality of life (SF-36) 6 months after admission. Baseline subject characteristics will be obtained, including height, bodyweight, medical history, use of medication, mental status (determined by the MMSE), smoking, use of alcohol, use of drugs, level of habitual physical activity (determined by PASE, Hip Fracture Recovery Scale), and quality of life (SF-36). The nutritional status of the patients will also be measured, using the MNA and MUST questionnaires. Lean body mass and bone mineral density will be determined by DEXA. In addition, blood samples will be analyzed for HbA1c, CRP, calcidiol, and TNF-a. | — |
Countries
Netherlands
Outcome results
None listed